Fig. 7From: Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinibTargeted IFN-stimulated gene RNA expression in total blood in patient compared with normal control. The ratio of the gene of interest to GAPDH in the normal control was set to 1. Data shown were mean ± SD of 3 three experiments, and each experiment was performed in duplicate. P: Patient, NC: normal controlBack to article page